Yinnuo Pharmaceutical

Yinnuo Pharmaceutical (also known as Innogen Pharma) is a science-driven biopharmaceutical company specializing in the development of innovative therapies for metabolic diseases, including type 2 diabetes, obesity, and MASH. Founded in 2014 by Dr. Wang Qinghua, the company leverages its proprietary recombinant protein biopharmaceutical technology platform to create long-acting humanized GLP-1 receptor agonists. Its flagship product, efsubaglutide alfa (Yinoqing), was approved in China in 2025 as the country's first domestically developed long-acting humanized GLP-1 receptor agonist. The company is currently expanding its clinical pipeline into weight management and veterinary medicine, and it is publicly traded on the Hong Kong Stock Exchange under the symbol 02591.HK.